TUCSON, Ariz., Jan. 28, 2020 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it.
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the HTG EdgeSeq Mouse mRNA Tumor Response Panel as a way to identify endogenous targets of cardiac fibrosis as reported in the September 2019 issue of Nature. In a mouse study designed and conducted by Haig Aghajanian et al., researchers sought to identify the cardiac immune response to fibrosis in mice and provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease. Using the HTG EdgeSeq Mouse mRNA Tumor Response Panel, researchers assessed the expression levels of 1,659 inflammatory and immune genes and found that 22 genes were differentially expressed between normal and CAR T-cell treated mice.
Top Ranked Momentum Stocks to Buy for May 14th
Increased product and product-related services revenue over prior year, benefitting from expanded menu of profiling assays and increased number of customers adopting technology.
Q4 2019 HTG Molecular Diagnostics Inc Earnings Call
TUCSON, Ariz., May 11, 2020 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will.
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 ...
TUCSON, Ariz., May 13, 2020 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its.
TUCSON, Ariz., Feb. 19, 2020 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced.
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the reproducibility of the HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA), as reported in a peer-reviewed paper in the December 2019 issue of Cell Reports. In a study designed and conducted by Paula M. Godoy et al, four miRNA profiling methods were compared using biofluids with both synthetic and biological micro-RNA (miRNA) samples. The paper, titled “Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms,” concluded that the HTG EdgeSeq platform using the miRNA WTA was the most reproducible and had the least detection bias when compared to the other technologies tested.
HTG Molecular Diagnostics Inc (HTGM) delivered earnings and revenue surprises of 0.00% and -2.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Q3 2019 HTG Molecular Diagnostics Inc Earnings Call
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Friday, December 13th in Boston, Massachusetts. The event will feature a presentation by Laura E. Benjamin, Ph.D., Founder and CEO, Oncologie, LTD, who will discuss the future of precision medicine and its potential to bring innovative new medicines to cancer patients globally. Oncologie and HTG are partnering on the development of biomarkers associated with Oncologie’s immuno-oncology pipeline.
HTG Molecular Diagnostics Inc (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TUCSON, Ariz., March 17, 2020 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it.
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) shareholders should be happy to see the share price up 15% in the last...
One thing we could say about the analysts on HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) - they aren't optimistic...
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced preliminary, unaudited financial results for the year ended December 31, 2019. Total revenue for the full year 2019 is expected to be approximately $19.2 million. Cash and cash equivalents are expected to be approximately $33.0 million, with an additional $3.3 million of restricted cash held in connection with a convertible note that will be included in the company’s current liabilities, as of December 31, 2019.